Skip to main content
Type at least 3 characters

33 articles

Original Research

Published on 04 Jan 2024

Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

in Therapy in Gastroenterology

  • Silvia Cruchet
  • Sandra Hirsch
  • Diana Villa-LĂłpez
  • Mucio Moreno-Portillo
  • Juan C. Palomo
  • Ana T. Abreu-Abreu
  • Juan M. Abdo-Francis
  • Carlos JimĂ©nez-GutiĂ©rrez
  • Martin Rojano
  • Gabriel LĂłpez-Velázquez
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1296048
  • 14,333 views
  • 3 citations

Original Research

Published on 23 Oct 2023

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

in Therapy in Gastroenterology

  • Giammarco Mocci
  • Arianna Cingolani
  • Giorgia OrrĂą
  • Carla Felice
  • Francesca Maria Onidi
  • Gianmarco Lombardi
  • Davide Checchin
  • Raffaele Colucci
  • Laurino Grossi
  • Antonio Ferronato
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1218228
  • 1,320 views
  • 1 citation